一项p16阳性口咽癌减强度治疗II期试验中诱导西妥昔单抗后的肿瘤免疫微环境变化
在一项p16阳性口咽癌II期临床减强度试验中,8例患者接受单次西妥昔单抗负荷剂量后1周行肿瘤活检,5例(62.5%)CD8+肿瘤浸润淋巴细胞增加,中位倍数变化+5.8(范围2.5-15.8);2例可评估RNA显示I型干扰素信号和角化通路快速改变。
要点
- 西妥昔单抗负荷剂量后1周,5/8例(62.5%)CD8+细胞浸润增加,中位倍数变化+5.8。
- 3/8例(37.5%)CD8+细胞无变化,中位倍数变化-0.85(范围0.8-1.1)。
- 2例可评估RNA中,西妥昔单抗诱导I型干扰素信号和角化通路快速转录组改变。
核心结论
- 西妥昔单抗可在1周内诱导可测量的促细胞毒性T细胞信号和免疫含量变化。
研究设计与样本
- II期临床减强度试验队列中,8例p16阳性口咽癌患者在单次西妥昔单抗负荷剂量前和1周后获取肿瘤活检。
主要发现
- 西妥昔单抗后1周,5例(62.5%)CD8+细胞浸润增加,中位(范围)倍数变化为+5.8(2.5-15.8)。
- 3例(37.5%)CD8+细胞无变化,中位(范围)倍数变化为-0.85(0.8-1.1)。
- 2例可评估RNA的患者中,西妥昔单抗诱导I型干扰素细胞信号和角化通路的快速肿瘤转录组改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to characterize early changes in CD8+ tumor-infiltrating lymphocytes and tumor transcriptomes after induction cetuximab in a cohort with p16-positive oropharyngeal cancer on a phase II clinical de-escalation trial. METHODS: Tumor biopsies were obtained before and 1 week after a single cetuximab loading dose in eight patients enrolled in a phase II trial of cetuximab and radiotherapy. Changes in CD8+ tumor-infiltrating lymphocytes and transcriptomes were assessed. RESULTS: One week after cetuximab, five patients (62.5%) had an increase in CD8+ cell infiltration with a median (range) fold change of +5.8 (2.5-15.8). Three (37.5%) had unchanged CD8+ cells (median [range] fold change of -0.85 [0.8-1.1]). In two patients with evaluable RNA, cetuximab induced rapid tumor transcriptome changes in cellular type 1 interferon signaling and keratinization pathways. CONCLUSIONS: Within 1 week, cetuximab induced measurable changes in pro-cytotoxic T-cell signaling and immune content.
引用
- Smith JD, Ludwig ML, Bhangale AD, et al. Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer. Head Neck. 2023. PMID: 36932871. doi:10.1002/hed.27344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。